ISIS Pharmaceuticals, Inc. (ISIS)

Mipomersen works. Side effects might be too great to be used for everyone, but it'll get used in HoFH patients.

Mipomersen will be the first Antisense drug to market in about 20 years and only the second antisense drug to market. Isis has approx. 18 drugs in its portfolio and an approval of Mipomersen will sharply increase its share price as investors will notice and value its pipeline better. Better cash position may also result in a possible buyout of the Co. however, due to the structure and complexity of its partnerships it is highly unlikely to be acquired. Isis will remain independent until it finds a true block buster drug with over 2B in revenue which it is Co marketing.

I expect Isis to trade in the 25-30 range in the next 12-18 months.

When the overly optimistic FOMC says that household spending will be "constrained" by sluggish income growth, ongoing job losses, lower household wealth, and tight credit AND Shanghai stocks hit a seven-week low, then you know this bear market rally is finally over!

Nice pipeline (http://www.isispharm.com/Pipeline/index.htm) of antisense (SiRNA) drugs, which they partner or license for commercialisation. Several drugs for multiple indications in P3. Cashflow is OK, likely to become profitable by end of year or sometime in 2010. They already have lot's of income even from drugs not already marketed due to license (of IP, have 1600 patents) & milestone payments.

Russell 2000 expected growth 26% or better

Antisense play that will either be a huge winner or a dismal failure. Been following this company for many years through trials that have fizzled out. However, the current pipeline looks promising and it is one resilient comany that takes a licking and keeps on ticking. Highly speculative but could produce a major breakthrough in the treatment of cancer, Type 2 diabetes, multiple sclerosis, etc. Great allianceswith Big Pharma also give one hope. ISIS is not for the faint of heart - it's almost a cult classic!

Best RNA tech. Huge investments from major pharms already.

My purpose and purpose only is to pick the opposite of whatever Jim Cramer picks to prove a point......

I have been a nurse for 18 years and I am a professor of nursing at a local college in Pitts, Pa.. Isis has a block buster drug being develop for cholestrol with Genzyme if all goes well. Their pipe line is full with exciting drugs. I see the RNA technology like I saw biologics 10 yrs ago. Not sure if anyone remembers Immunex, it outperformed Cisco and was bought out, they develop the block buster drug for rhemutoid arthritis. I did owned Elan, but sold in Dec., I saw trouble coming with their Alzheimers study and more PML cases coming for Tsyabri. Elan was $34 on Monday and it is under $10. Jim Cramer also did not like Elan. I must say Pete N. on Fast money was wrong about Elan, but I feel he is correct about Isis. I made most of money in biotech over the years in the stock market.

The analysts know more than you do. This is a winner

LOVED THIS STOCK SINCE SEPTEMBER 2007

RNA therapeutics

Revolutionary approach to medical drug formulation.

ISIS has a boat load of patents and is a leader in iRNA which shows great promise. Big pharma needs the ISIS pipeline. ISIS will be acquired within the next year.

Company entering first part of Phase III trials in partnership with Genzyme for a drug targeting a population of persons with extreme cases of LDL not affected by statin based drugs. Have received guidelines from FDA on a "fast-track" development and approval program.lf results continue as presently experienced should be a market entry by 2010.

My spouses family has a history of early deaths related to this extreme form of high cholesterol. This may be their life line.

Please use the daily charts before you read farther to understand what I mean.

Most of the time when the price of this stock gaps up, it goes down. Its noticeable gap up was on 8-Jan-2008 only to go down for several weeks. The investors of this stock are using those gaps up as their exit points by selling them.

Eventually it gap down on 28-April-2008 and as expected it went down for several days. And it gap up on 12-May-2008. Do I expect a new uptrend? Maybe not knowing the history of the stock’s pattern.

Well as you know this is a biopharmaceutical company. Stocks on this industry are very volatile which probably explains the chart pattern.

Best of the small to mid-cap bio-techs. Large diversified group of drugs in the pipeline. 66% growth to target price.

The stock just pulled back 29% because the FDA pushed back the approval date. This does not mean anything about the approval itself, simply the FDA needs more time to get itself organized.

Just waiting for the acquisition to happen. Big Pharm has to start buying these companies to fill their pipeline with new drugs!